Personalis, Inc. (NASDAQ:PSNL) Stock Has Consensus Price Target of $15.29

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) has been given an average recommendation of “Hold” by the ten brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $15.29.

Several equities research analysts have recently weighed in on PSNL shares. UBS Group lowered Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Thursday, October 15th. Zacks Research raised Personalis from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Craig Hallum cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a report on Monday, August 24th. Finally, BTIG Research cut Personalis from a “buy” rating to a “neutral” rating in a report on Tuesday, October 6th.

View Our Latest Analysis on Personalis

Personalis Trading Down 3.1%

Personalis stock opened at $14.27 on Monday. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89. The firm has a market cap of $1.55 billion, a PE ratio of -12.20 and a beta of 2.40. The stock’s 50 day simple moving average is $15.89 and its two-hundred day simple moving average is $11.74.

Personalis (NASDAQ:PSNL – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06). Personalis had a negative return on equity of 49.53% and a negative net margin of 147.74%. The company had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $21.54 million.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher Hall sold 7,459 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $120,984.98. Following the completion of the sale, the chief executive officer directly owned 228,527 shares in the company, valued at $3,706,707.94. The trade was a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $33,542.96. Following the transaction, the senior vice president directly owned 90,257 shares in the company, valued at $1,463,968.54. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 16,456 shares of company stock valued at $266,916. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in the company. Merck & Co. Inc. acquired a new position in Personalis during the second quarter valued at $188,202,236. BlackRock Inc. acquired a new position in Personalis in the 2nd quarter valued at approximately $94,905,000. Bank of America Corp DE acquired a new stake in Personalis during the second quarter worth $24,395,000. AIGH Capital Management LLC bought a new position in shares of Personalis during the 2nd quarter worth approximately $22,981,000. Finally, Aberdeen Group plc boosted its stake in Personalis by 39.1% in the third quarter. Aberdeen Group plc now owns 5,211,939 shares of the company’s stock worth $84,850,000 after purchasing an additional 1,464,649 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

(Get Free Report)

Personalis is a cancer genomics company that develops sequencing and data-analysis tools for cancer research and personalized cancer care. Its services support pharmaceutical and biotechnology companies, academic researchers, and clinicians studying cancer and evaluating treatments. The company’s offerings include NeXT Personal, a blood-based test designed to detect molecular residual disease and monitor cancer recurrence using circulating tumor DNA. Personalis also provides tumor profiling and immunogenomics services that analyze cancer-related genetic changes and features of the tumor immune environment.

See Also

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.